Moreover, combination effects of mTOR inhibitors and HDAC inhibition were seen independent of the AR status, thus potentially offering an opportunity for hard-to-treat, castration-resistant prostate cancer [189]. This evidence concerns the gene HDAC9 and prostate carcinoma.